Articles

  1. Kemwell Overview 3/29/2012
    Manufacturing customers include top pharmaceutical companies – Allergan, Bayer, GSK, J&J, Pfizer, Teva, and Novartis, as well as small emerging biotech.
  2. Sterile Clinical Trial Material Formulation & Filling 3/26/2012
    DSM offers sterile clinical trial formulation and filling that meets the unique needs of global pharmaceutical and biotech customers.
  3. Cytotoxic Formulation & Filling 3/26/2012
    DSM expanded their commercial-scale sterile pharmaceutical services by offering filling and lyophilization of cytotoxic products.
  4. Accelerated Drug Development: The Promise Is In The Process 3/21/2012

    In 1993, the FDA issued the call to the pharmaceutical industry to streamline the drug development process from discovery to First In Man. By Jan-Olav Henck, Ph.D., Chief Scientific Officer, Aptuit LLC

  5. Brochure: RHOBUST® Downstream Processing Technology 2/22/2012
    Rhobust® technology is a downstream processing technology for the manufacturing of recombinant proteins and antibodies.
  6. Brochure: XD® Technology: Improve Biopharmaceutical Production 2/22/2012
    DSM's XD® Technology has been developed to drive yield improvements in the production of biopharmaceuticals.
  7. Brochure: Finished Dosage Forms 2/21/2012
    DSM is a global provider of finished dosage form manufacturing and related services to pharmaceutical and biopharmaceutical markets.
  8. Brochure: Biologics Contract Manufacturing & Technology Solutions 1/30/2012

    DSM provides turn-key biologic manufacturing solutions, contract manufacturing for preclinical development, clinical trials or commercial supply and reduced cost, risk, and time to market.

  9. Brochure: Pharma Sterile Dosage Forms 1/30/2012

    DSM offers pharmaceutical and biopharmaceutical customers a lyophilization system with unique benefits. It has the precision to serve increasingly demanding lyophilization cycles, a critical requirement for successful product launches and high commercial yields. 

  10. Combination Products 2.0: Applying The New FDA Regulations 1/20/2012
    Combination products, those that contain medical devices embedded with pharmaceutical or biologic components, have become a large and growing segment of the medical device market. Some analysts estimate they represent over 30% of all new product submissions to the FDA. By Steven Richter, Ph.D